These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22914606)

  • 1. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
    Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
    Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
    Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
    J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers.
    Forslund A; Zeng Z; Qin LX; Rosenberg S; Ndubuisi M; Pincas H; Gerald W; Notterman DA; Barany F; Paty PB
    Mol Cancer Res; 2008 Feb; 6(2):205-11. PubMed ID: 18314481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
    Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
    Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
    Menin C; Scaini MC; De Salvo GL; Biscuola M; Quaggio M; Esposito G; Belluco C; Montagna M; Agata S; D'Andrea E; Nitti D; Amadori A; Bertorelle R
    J Natl Cancer Inst; 2006 Feb; 98(4):285-8. PubMed ID: 16478747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.
    Abderrahmane R; Louhibi L; Moghtit FZ; Boubekeur A; Benseddik K; Boudjema A; Benrrahal F; Aberkane M; Fodil M; Saidi-Mehtar N
    Pathol Oncol Res; 2015 Jul; 21(3):629-35. PubMed ID: 25537146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
    Han JY; Lee GK; Jang DH; Lee SY; Lee JS
    Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
    Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
    Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
    Zhang X; Pageon L; Post SM
    Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.
    Tu HF; Chen HW; Kao SY; Lin SC; Liu CJ; Chang KW
    Radiother Oncol; 2008 May; 87(2):243-52. PubMed ID: 18423915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome.
    Sotamaa K; Liyanarachchi S; Mecklin JP; Järvinen H; Aaltonen LA; Peltomäki P; de la Chapelle A
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6840-4. PubMed ID: 16203772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
    Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
    J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
    Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
    DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.